Report Misleads on Drug Prices

Blog

The Pharmaceutical Research and Manufacturers of America (PhRMA) released yet another report designed to obfuscate the issue of sky-rocketing drug prices. Once again, PhRMA turned its sights on hospitals in just another example of PhRMA choosing to blame others rather than looking inward at the... read more

Topic: Access and Coverage
Tag: drug prices

Reining in drug prices

Blog

A Senate committee today shined the spotlight on the wave of high and unexpected increases in prescription drug costs that puts an incredible financial strain on hospitals and health systems and threaten our ability to provide high quality care each and every day.

In a statement submitted to the... read more

Topic: Advocacy and Public Policy
Tag: drug prices

High Drug Prices Hurt Everyone

Blog

More evidence this week of how unchecked drug price increases are forcing hospitals to make tough choices and are a serious economic threat to the patients and communities we serve. An AHA/Federation of American Hospitals-commissioned report by the University of Chicago’s NORC showed inpatient hospital... read more

Topic: Advocacy and Public Policy
Tag: drug prices

Hospitals, not pharmaceutical manufacturers, are preserving and protecting the safety net

Blog

A group financed by the pharmaceutical industry is hosting a meeting today on the 340B Drug Pricing Program with the goal of “Preserving the True Safety Net.” But what the meeting really will be about is the pharmaceutical industry – with their skyrocketing prescription drug prices and huge profits –... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, Community benefit, access, drug prices

Valeant Needs to Keep Its Promises

Blog

A recent article in the New York Times highlights the yet-to-be-fulfilled promises made by Valeant Pharmaceuticals International to the U.S. Congress. Valeant had said it would give hospitals discounts of as much as 30 percent on two of its expensive heart drugs. But those discounts never materialized and... read more

Topic: Advocacy and Public Policy
Tag: drug prices

Checking Unchecked Rx Prices

Blog

Unchecked drug price increases hit both patients and hospitals hard. Since 2008, brand name drugs prices have increased 127 percent compared with an 11 percent rise in consumer prices. These increases cut deep into both hospital budgets and services and undermine patient and community health, particularly... read more

Topic: Advocacy and Public Policy
Tag: drug prices

Changing 340B is the wrong prescription for addressing skyrocketing pharmaceutical costs

Blog

The rapidly rising costs of prescription drugs is causing significant financial challenges for patients and their care providers.

Many groups, including the AHA, are evaluating options for addressing this important issue. However, one recent proposal, which is seriously misguided, would reduce a program... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, access, price, drug prices

Stop Unsustainable Drug Prices

Blog

Today’s New York Times provides arguments from drug companies justifying the excessive jump in pharmaceutical prices in recent years, saying the higher prices won’t impact patients. 

Hospitals’ top priority is providing patients with safe and effective care, but the skyrocketing costs of pharmaceuticals... read more

Topic: Access and Coverage
Tags: access, price, drug prices

Drug Price Hikes Hurt Everyone

Blog

A Senate committee this week put the spotlight on the wave of increases in the cost of medications. While those truly innovative medicines that save lives and ease suffering are certainly valued by all, the committee’s hearing focused on some of the more troubling of the pharmaceutical industry’s tactics... read more

Topic: Advocacy and Public Policy
Tag: drug prices

Protect Patients. Preserve 340B.

Blog

More than 20 years ago, Congress created the 340B Drug Pricing Program to allow eligible hospitals and health systems to stretch limited resources and expand access to care for vulnerable patients. But despite a proven track record of increasing patient access to vital medical services and decreasing... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, access, price, drug prices

Keyword Search

Date